Deucravacitinib (Sotyktu) for Plaque Psoriasis

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2023 . Peer-reviewed

Data sources: Crossref

The Medical Letter on Drugs and Therapeutics

Article . 2023

Data sources: Europe PubMed Central

Deucravacitinib (Sotyktu) for Plaque Psoriasis

descriptionPublicationkeyboard_double_arrow_right Article 20 Feb 2023Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 65, pages 29-31 (eissn: 1523-2859,

Copyright policy )

doi: 10.58347/tml.2023.1670b

pmid: 36757835

Deucravacitinib (Sotyktu) for Plaque Psoriasis

- Summary
- Subjects
- Metrics

Abstract

The FDA has approved deucravacitinib (Sotyktu – BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is the first selective TYK2 inhibitor to be approved in the US for any indication.

Keywords

Treatment Outcome, Heterocyclic Compounds, Anti-Inflammatory Agents, Non-Steroidal, Humans, Psoriasis, Severity of Illness Index

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average